BioCentury
ARTICLE | Clinical News

COTI-2: Phase I started

February 22, 2016 8:00 AM UTC

Critical Outcome began an open-label, U.S. Phase I trial to evaluate oral COTI-2 in up to 46 patients with platinum-resistant, recurrent ovarian, endometrial or cervical cancer. Patients will receive ...